{
    "clinical_study": {
        "@rank": "109313", 
        "arm_group": [
            {
                "arm_group_label": "Udenafil 150 mg + Udenafil 150 mg", 
                "arm_group_type": "Experimental", 
                "description": "Udenafil 150 mg, tablet, orally, once on Day 1,  followed by udenafil 150 mg, tablet, orally, once on Day 3."
            }, 
            {
                "arm_group_label": "Udenafil 150 mg + Placebo", 
                "arm_group_type": "Experimental", 
                "description": "Udenafil 150 mg, tablet, orally, once on Day 1,  followed by placebo, tablet, orally, once on Day 3."
            }, 
            {
                "arm_group_label": "Placebo + Udenafil 150 mg", 
                "arm_group_type": "Experimental", 
                "description": "Placebo, tablet, orally, once on Day 1, followed by udenafil 150 mg, tablet, orally, once on Day 3."
            }, 
            {
                "arm_group_label": "Placebo + Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo, tablet, orally, once on Day 1, followed by placebo, tablet, orally, once on Day 3."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the safety and tolerability of Udenafil 150 mg\n      compared to placebo."
        }, 
        "brief_title": "Safety and Pharmacokinetic Profile of Udenafil in Healthy Mexican Adults", 
        "completion_date": {
            "#text": "August 2013", 
            "@type": "Actual"
        }, 
        "condition": [
            "Erectile Dysfunction", 
            "Phosphodiesterase 5 Inhibitor"
        ], 
        "condition_browse": {
            "mesh_term": "Erectile Dysfunction"
        }, 
        "detailed_description": {
            "textblock": "The drug being tested in this study is called Udenafil. Udenafil is being tested to\n      determine a safe and well-tolerated dose. This study will look at vital signs, laboratory\n      tests and side effects in people who take Udenafil.\n\n      The study will enroll approximately 84 patients. Participants will be randomly assigned (by\n      chance) and by blocks to assure balanced groups (i.e. same number of participants) to one of\n      the four treatment schemes\u2014which will remain undisclosed to the patient and study doctor\n      during the study (unless there is an urgent medical need):\n\n        -  a) Udenafil-Udenafil\n\n        -  b) Udenafil- Placebo\n\n        -  c) Placebo-Udenafil\n\n        -  d) Placebo-Placebo\n\n      All participants will be asked to take one tablet on Day 1 and one tablet on Day 3.\n\n      This single-centre trial will be conducted in Mexico. The overall time to participate in\n      this study is up to 7 days. Participants will make 3 visits to the clinic, including 5 days\n      confinement to the clinic, and will be contacted by telephone 15 days after last visit to\n      the clinic for a follow-up assessment."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Sign a letter of informed consent prior to performing any procedure.\n\n          2. Male\n\n          3. Clinically healthy\n\n          4. Age between 18 and 55 years old.\n\n          5. Body Mass Index (BMI) between 18.5 and 24.9.\n\n          6. Capability and disposition to attend clinical intervention period\n\n        Exclusion Criteria:\n\n          1. Current use of any allopathic, over the counter (OTC) (e.g. nutritional supplements)\n             or alternative (e.g. herbal) medication within two weeks prior to trial initiation.\n\n          2. History of psychiatric diseases.\n\n          3. History of drug abuse (alcohol, tobacco or any other).\n\n          4. Chronic consumption of caffeine (coffee, cola, green tea, St. Johns Wort).\n\n          5. Laboratory tests with clinically significant alterations.\n\n          6. Intestinal disorders that may modify absorption.\n\n          7. History of allergy to the drug or related drugs.\n\n          8. Blood donation within 45 days prior to study initiation.\n\n          9. Participation in a clinical trial within 2 months prior to study initiation.\n\n         10. History of orthostatic alterations or presyncope.\n\n         11. Vegetarian diet or other peculiar dietary habits which would interfere the\n             participant's acceptance to standardized meals.\n\n         12. Inability to communicate or social vulnerability."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "83", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "October 17, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01967264", 
            "org_study_id": "PK-MX031", 
            "secondary_id": "U1111-1146-1315"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Udenafil 150 mg + Udenafil 150 mg", 
                    "Udenafil 150 mg + Placebo", 
                    "Placebo + Udenafil 150 mg"
                ], 
                "description": "Udenafil tablets", 
                "intervention_name": "Udenafil", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Udenafil 150 mg + Placebo", 
                    "Placebo + Udenafil 150 mg", 
                    "Placebo + Placebo"
                ], 
                "description": "Placebo tablets", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Udenafil"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Drug therapy", 
        "lastchanged_date": "October 17, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Quer\u00e9taro", 
                    "country": "Mexico"
                }
            }
        }, 
        "location_countries": {
            "country": "Mexico"
        }, 
        "number_of_arms": "4", 
        "official_title": "A Randomized, Double Blind, Placebo Controlled Study to Evaluate the Safety Profile and Pharmacokinetic Parameters of Udenafil 150 mg in Healthy Mexican Subjects.", 
        "overall_official": {
            "affiliation": "Takeda", 
            "last_name": "Medical Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Mexico: Federal Commission for Sanitary Risks Protection", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "August 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "AEs will be evaluated by monitoring participants vital signs, laboratory tests (blood chemistry, hematology, coagulation and serology tests, urianalysis), electrocardiography (ECG).", 
            "measure": "Participants with Adverse Events", 
            "safety_issue": "Yes", 
            "time_frame": "3 Weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01967264"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "AUC(0-last) is a measure of total plasma exposure to the drug from Time 0 to the last measured concentration above the lower limit of quantification (LLOQ).", 
                "measure": "AUC(0-last): Area Under the Plasma Concentration-Time Curve From Time 0 to the Last Measured Concentration Above the Lower Limit of Quantification", 
                "safety_issue": "No", 
                "time_frame": "Predose and at 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 5, 7, 9, 12, 24, 36 and 48 hours post-dose"
            }, 
            {
                "description": "Area under the plasma concentration-time curve from time zero extrapolated to infinity.", 
                "measure": "AUC(0-inf): Area Under the Plasma Concentration-time Curve from Time 0 to Infinity", 
                "safety_issue": "No", 
                "time_frame": "Predose and at 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 5, 7, 9, 12, 24, 36 and 48 hours post-dose"
            }, 
            {
                "description": "Maximum observed plasma concentration (Cmax) is the peak plasma concentration of a drug after administration, obtained directly from the plasma concentration-time curve.", 
                "measure": "Cmax: Maximum Observed Plasma Concentration", 
                "safety_issue": "No", 
                "time_frame": "Predose and at 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 5, 7, 9, 12, 24, 36 and 48 hours post-dose"
            }, 
            {
                "description": "Time to reach the maximum plasma concentration (Cmax), equal to time (hours) to Cmax.", 
                "measure": "Tmax: Time to Reach the Maximum Plasma Concentration", 
                "safety_issue": "No", 
                "time_frame": "Predose and at 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 5, 7, 9, 12, 24, 36 and 48 hours post-dose"
            }, 
            {
                "description": "Terminal phase elimination half-life (T1/2) is the time required for half of the drug to be eliminated from the plasma.", 
                "measure": "Terminal Phase Elimination Half-life (T1/2)", 
                "safety_issue": "No", 
                "time_frame": "Predose and at 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 5, 7, 9, 12, 24, 36 and 48 hours post-dose"
            }
        ], 
        "source": "Takeda", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Takeda", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}